(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 92.62% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.34%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.56%.
Zymeworks's revenue in 2026 is $37,127,000.On average, 13 Wall Street analysts forecast ZYME's revenue for 2026 to be $21,907,246,474, with the lowest ZYME revenue forecast at $18,894,317,101, and the highest ZYME revenue forecast at $27,684,038,284. On average, 12 Wall Street analysts forecast ZYME's revenue for 2027 to be $23,245,537,759, with the lowest ZYME revenue forecast at $10,639,628,596, and the highest ZYME revenue forecast at $35,964,272,116.
In 2028, ZYME is forecast to generate $18,829,034,599 in revenue, with the lowest revenue forecast at $4,659,183,764 and the highest revenue forecast at $32,187,111,718.